Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - ivabradine - film coated tablet - 7.5 milligram - other cardiac preparations

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

rowex ltd - ivabradine - film-coated tablet - 5 milligram(s) - other cardiac preparations; ivabradine

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

rowex ltd - ivabradine - film-coated tablet - 7.5 milligram(s) - other cardiac preparations; ivabradine

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

les laboratoires servier - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectorisivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated:in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.treatment of chronic heart failureivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

"anpharm" przedsiębiorstwo farmaceutyczne s.a. - ivabradine - angina pectoris; heart failure - other cardiac preparations - symptomatic treatment of chronic stable angina pectorisivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated:in adults unable to tolerate or with a contra-indication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal betablocker dose.treatment of chronic heart failureivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

les laboratoires servier - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectoris ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated :in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.treatment of chronic heart failure ivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Կանադա - անգլերեն - Health Canada

torrent pharmaceuticals limited - levetiracetam - tablet - 250mg - levetiracetam 250mg - miscellaneous anticonvulsants

Կանադա - անգլերեն - Health Canada

torrent pharmaceuticals limited - levetiracetam - tablet - 500mg - levetiracetam 500mg - miscellaneous anticonvulsants

Կանադա - անգլերեն - Health Canada

torrent pharmaceuticals limited - levetiracetam - tablet - 750mg - levetiracetam 750mg - miscellaneous anticonvulsants

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

parnell technologies pty ltd - gonadorelin acetate (unii: 2rg1xq1nyj) (gonadorelin - unii:9o7312w37g) - gonadorelin 100 ug in 1 ml - indications and dosage: cystic ovaries gonabreed is indicated for the treatment of ovarian follicular cysts in dairy cattle. ovarian cysts are non-ovulated follicles with incomplete luteinization which result in nymphomania or irregular estrus. historically, cystic ovaries have responded to an exogenous source of luteinizing hormone (lh) such as human chorionic gonadotrophin. gonabreed initiates release of endogenous lh to cause ovulation and luteinization. the recommended intravenous or intramuscular dosage of gonabreed is 100 mcg (1 ml) per cow. reproductive synchrony gonabreed is indicated for use with cloprostenol sodium to synchronize estrous cycles to allow for fixed time artificial insemination (ftai) in lactating dairy cows and beef cows. the recommended intramuscular dosage of gonabreed is 100 mcg (1 ml) per cow, used in reproductive synchrony programs similar to the following: administer the first gonabreed injection (1 ml) at time 0. administer 500 mcg cloprostenol (as cloprostenol sodium) by intra